JP7100639B2 - Ｃｘｃｒ４アンタゴニストおよび使用方法 - Google Patents

Ｃｘｃｒ４アンタゴニストおよび使用方法 Download PDF

Info

Publication number
JP7100639B2
JP7100639B2 JP2019533297A JP2019533297A JP7100639B2 JP 7100639 B2 JP7100639 B2 JP 7100639B2 JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019533297 A JP2019533297 A JP 2019533297A JP 7100639 B2 JP7100639 B2 JP 7100639B2
Authority
JP
Japan
Prior art keywords
ipr
lys
gly
peptide
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019533297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534893A (ja
JP2019534893A5 (https=
Inventor
チャン，ユンゲ
ツェン ヤン，リャン
Original Assignee
メインライン バイオサエンシズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メインライン バイオサエンシズ filed Critical メインライン バイオサエンシズ
Publication of JP2019534893A publication Critical patent/JP2019534893A/ja
Publication of JP2019534893A5 publication Critical patent/JP2019534893A5/ja
Application granted granted Critical
Publication of JP7100639B2 publication Critical patent/JP7100639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019533297A 2016-09-06 2017-09-05 Ｃｘｃｒ４アンタゴニストおよび使用方法 Expired - Fee Related JP7100639B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384132P 2016-09-06 2016-09-06
US62/384,132 2016-09-06
US201762505064P 2017-05-11 2017-05-11
US62/505,064 2017-05-11
PCT/US2017/050106 WO2018048806A1 (en) 2016-09-06 2017-09-05 Cxcr4 antagonists and methods of use

Publications (3)

Publication Number Publication Date
JP2019534893A JP2019534893A (ja) 2019-12-05
JP2019534893A5 JP2019534893A5 (https=) 2020-08-20
JP7100639B2 true JP7100639B2 (ja) 2022-07-13

Family

ID=61281979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533297A Expired - Fee Related JP7100639B2 (ja) 2016-09-06 2017-09-05 Ｃｘｃｒ４アンタゴニストおよび使用方法

Country Status (6)

Country Link
US (2) US10351601B2 (https=)
EP (1) EP3509612A4 (https=)
JP (1) JP7100639B2 (https=)
CN (1) CN109922818B (https=)
CA (1) CA3032885C (https=)
WO (1) WO2018048806A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639379B2 (en) * 2017-09-05 2020-05-05 Mainline Biosciences Llc High affinity CXCR4 selective binding conjugate and method for using the same
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
CN115003684A (zh) * 2020-01-26 2022-09-02 主线生物科学有限公司 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法
CN118852348A (zh) * 2022-02-11 2024-10-29 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
GB2628421A (en) * 2023-03-24 2024-09-25 Syntherix Ltd Peptides and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529957A (ja) 2007-05-30 2010-09-02 イーライ リリー アンド カンパニー 環状ペプチドｃｘｃｒ４アンタゴニスト
CN102626522A (zh) 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
US20130079292A1 (en) 2010-01-26 2013-03-28 Consiglio Nazionale Delle Ricerche Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses
JP2015521204A (ja) 2012-06-06 2015-07-27 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60103052T2 (de) * 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP1582207A4 (en) * 2002-12-26 2008-03-05 Ajinomoto Kk HEMMER FOR OUTBREAKING AND PROGREDIENCE OF LIVER CANCER
CA2569807A1 (en) * 2004-06-18 2005-12-29 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of hiv infections
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
JP6294227B2 (ja) * 2011-10-07 2018-03-14 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ Ｆｐｒ１の阻害剤としてのテンプレート固定ペプチド模倣薬
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529957A (ja) 2007-05-30 2010-09-02 イーライ リリー アンド カンパニー 環状ペプチドｃｘｃｒ４アンタゴニスト
US20130079292A1 (en) 2010-01-26 2013-03-28 Consiglio Nazionale Delle Ricerche Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses
CN102626522A (zh) 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
JP2015521204A (ja) 2012-06-06 2015-07-27 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PENG, S.-B. et al.，Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models，Molecular Cancer Therapeutics，Vol. 14, No. 2，2014年，P. 480-490
YOSHIKAWA, Y. et al.，Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4-FC131 interactions，Bioorganic & Medicinal Chemistry Letters，2012年，Vol. 22，P. 2146-2150

Also Published As

Publication number Publication date
EP3509612A1 (en) 2019-07-17
CN109922818B (zh) 2024-02-20
JP2019534893A (ja) 2019-12-05
US10870681B2 (en) 2020-12-22
CA3032885A1 (en) 2018-03-15
CN109922818A (zh) 2019-06-21
EP3509612A4 (en) 2021-07-21
US10351601B2 (en) 2019-07-16
WO2018048806A1 (en) 2018-03-15
US20180066021A1 (en) 2018-03-08
CA3032885C (en) 2023-06-20
US20190309023A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
JP7100639B2 (ja) Ｃｘｃｒ４アンタゴニストおよび使用方法
US11845808B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN101678213B (zh) 环肽cxcr4拮抗剂
ES3058577T3 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
US12297294B2 (en) Cortistatin analogues for the treatment of inflammatory and/or immune diseases
CN115279782A (zh) 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
KR20230053615A (ko) 접합된 헵시딘 모방체
CN114341161A (zh) 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
CA3065086A1 (en) High affinity cxcr4 selective binding conjugate and method for using the same
EP4182023A1 (en) Inhibitors of complement factor c3 and their medical uses
EP3122369B1 (en) Cyclic prosaposin peptides and uses thereof
US10639379B2 (en) High affinity CXCR4 selective binding conjugate and method for using the same
US20240082346A1 (en) Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same
OA21041A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
BR122024027151A2 (pt) Peptídeos monocíclicos e seus usos
BR122024027157A2 (pt) Inibidores peptídicos monocíclicos, composição farmacêutica e seus usos
BR122024027142A2 (pt) Inibidor peptídico do receptor de interleucina-23, composição farmacêutica, e uso dos mesmos
HK1233930A1 (en) Cyclic prosaposin peptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220701

R150 Certificate of patent or registration of utility model

Ref document number: 7100639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees